5
Registered trials
3
Recruiting
5
Unique sponsors
12
Unique IMPs
3
Commercial trials
Drug classes (ATC)
—
ATC code not specified
2
L
Oncology (ATC L)
3
N
Neurology/Psychiatry (ATC N)
3
Mechanism of action (INN-stem analysis)
Unknown / small molecule
3 substances
Monoclonal antibody (tumor, humanized)
2 substances
BTK inhibitor
2 substances
Monoclonal antibody
1 substance
IMiD
1 substance
Monoclonal antibody (chimeric)
1 substance
Monoclonal antibody (immune, humanized)
1 substance
CAR-T cell therapy
1 substance
Phase III:
1
Phase II:
2
Phase I/II:
1
Phase I:
1
Phase III
1 trial-
RecruitingF. Hoffmann-La Roche AG CommercialBENDAMUSTINE HYDROCHLORIDE; GLOFITAMAB; LENALIDOMIDE; OBINUTUZUMAB; RITUXIMAB; TOCILIZUMAB
Phase II
2 trials-
ExpiredFondazione IRCCS Istituto Nazionale Dei Tumori AcademicBREXUCABTAGENE AUTOLEUCEL; IBRUTINIB
-
EndedFondazione Italiana Linfomi Ets AcademicIMP not specified
Phase I/II
1 trial-
RecruitingBeOne Medicines AG CommercialBGB-16673; GLOFITAMAB; MOSUNETUZUMAB; N-[4-({[(1R,4R)-4-HYDROXY-4-METHYLCYCLOHEXYL]METHYL}AMINO)-3- NITROBENZENE-1-SULFONYL]-4-(2-{(2S)-2-[2-(PROPAN-2-YL)PHENYL]PYRROLIDIN1-YL}-7-AZASPIRO[3.5]NONAN-7-YL)-2-[(1H-PYRROLO[2,3-B]PYRIDIN-5- YL)OXY]BENZAMIDE; OBINUTUZUMAB; ZANUBRUTINIB
Phase I
1 trial-
RecruitingExscientia AI Limited CommercialIMP not specified
Sponsor activity
| Sponsor | Type | Trials | Phases | Recruiting |
|---|---|---|---|---|
| Exscientia AI Limited | Commercial | 1 | Phase I | 1 |
| F. Hoffmann-La Roche AG | Commercial | 1 | Phase III | 1 |
| BeOne Medicines AG | Commercial | 1 | Phase I/II | 1 |
| Fondazione IRCCS Istituto Nazionale Dei Tumori | Academic | 1 | Phase II | 0 |
| Fondazione Italiana Linfomi Ets | Academic | 1 | Phase II | 0 |
New trials by year
2022
1
2023
2
2025
2